{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:57:42Z","timestamp":1792033062623,"version":"4.4.0"},"reference-count":22,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"\n Importance<\/jats:title>\n Transthyretin cardiac amyloidosis (ATTR-CM) is associated with poor prognosis and significant morbidity and mortality, yet existing staging systems have limited ability to accurately predict outcomes in contemporary patient populations.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To develop and validate a machine learning (ML)\u2013based prognostic model for patients with ATTR-CM.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This multicenter cohort study, including specialized referral centers for cardiac amyloidosis, used data from patients with confirmed ATTR-CM in the Swiss Cardiac Amyloidosis Registry (February 2018 to November 2025) and the Cardiac Amyloidosis Registry of the Medical University of Vienna (July 2014 to February 2025). A random survival forest model was developed and evaluated through internal-external cross-validation, with each center iteratively held out for validation. The model was compared with the National Amyloidosis Centre and Mayo Clinic staging systems. Data analysis was conducted from December 2025 to February 2026.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Clinical, demographic, medication, laboratory, and echocardiographic variables were used to train an ML-based time-to-event prediction model.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was defined as a composite event of all-cause mortality and hospitalization for heart failure.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 850 patients (median [IQR] age, 79 [74-83] years; 750 [88.2%] male) were included across 3 cohorts (from Bern, Switzerland [Bern-Swiss cohort], n\u2009=\u2009352; the other centers from Switzerland combined [Other-Swiss cohort], n\u2009=\u2009260; and Vienna, Austria [Vienna cohort], n\u2009=\u2009238). The random survival forest model demonstrated good discrimination across all held-out cohorts, with Harrell concordance indices of 0.74 (95% CI, 0.69-0.78), 0.77 (95% CI, 0.69-0.83), and 0.72 (95% CI, 0.67-0.77) for the Bern-Swiss, Other-Swiss, and Vienna cohorts, respectively, and 3-year area under the curve (AUC) of 0.73 (95% CI, 0.66-0.80), 0.80 (95% CI, 0.70-0.88), and 0.75 (95% CI, 0.67-0.83), respectively. The model showed improved discrimination compared with the National Amyloidosis Centre and Mayo Clinic staging systems, with Harrell concordance indices 2% to 10% higher and 3-year AUC improvements ranging from 3% to 19% across cohorts and scoring systems. Calibration was generally acceptable across cohorts and time points. Model performance remained satisfactory in the subgroup of patients receiving disease-modifying therapy. Explainability analyses identified clinically plausible drivers of risk.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n An ML-based time-to-event prediction model demonstrated promising predictive performance and showed improved discrimination compared with established staging systems in patients with ATTR-CM, supporting its potential for individualized prognostication.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamacardio.2026.3496","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:30:16Z","timestamp":1787920216000},"page":"932","source":"Crossref","is-referenced-by-count":1,"title":["Machine Learning\u2013Driven Risk Prediction Model in Transthyretin Amyloid Cardiomyopathy"],"prefix":"10.1001","volume":"11","author":[{"given":"Giovanni","family":"Baj","sequence":"first","affiliation":[{"name":"Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"},{"name":"Department of Digital Medicine, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Ciocca","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"},{"name":"Department of Digital Medicine, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooya","family":"Mohammadi Kazaj","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"},{"name":"Department of Digital Medicine, University of Bern, Bern, Switzerland"},{"name":"Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"},{"name":"Department of Digital Medicine, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annina A.","family":"Studer Bruengger","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Institute for Radiology and Nuclear Medicine, Stadtspital Triemli, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon F.","family":"St\u00e4mpfli","sequence":"additional","affiliation":[{"name":"Heart Center Lucerne, Luzerner Kantonsspital, Lucerne, Switzerland"},{"name":"Center for Molecular Cardiology, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas F.","family":"Ehl","sequence":"additional","affiliation":[{"name":"Department of Cardiology, HOCH, Cantonal Hospital St Gallen, St Gallen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hugelshofer","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Cardio-Vascular Department, University Hospital of Canton Vaud, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otmar","family":"Pfister","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Heart Center, University Hospital Basel, University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00eblle","family":"Lehmann","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Ryffel","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"},{"name":"Department of Digital Medicine, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Hunziker","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Poledniczek","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kammerlander","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George C. M.","family":"Siontis","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"},{"name":"Associate Editor, JAMA Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz J.","family":"Hundertmark","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Nitsche","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Shiri","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"},{"name":"Department of Digital Medicine, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Gr\u00e4ni","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"},{"name":"Department of Digital Medicine, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"hoi260047r1","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac amyloidosis due to transthyretin protein: a review.","volume":"331","author":"Ruberg","year":"2024","journal-title":"JAMA"},{"issue":"22","key":"hoi260047r2","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review.","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"hoi260047r3","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association.","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"issue":"11","key":"hoi260047r4","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"hoi260047r5","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system.","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"30","key":"hoi260047r6","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis.","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"issue":"22","key":"hoi260047r7","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years.","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"issue":"2","key":"hoi260047r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2024.101568","article-title":"Accuracy of established prognostic staging systems for cardiac transthyretin amyloidosis in the tafamidis era.","volume":"4","author":"M\u00fcller","year":"2025","journal-title":"JACC Adv"},{"issue":"1","key":"hoi260047r9","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.036755","article-title":"Predictors of early death in patients with wild-type transthyretin cardiac amyloidosis.","volume":"14","author":"Milani","year":"2025","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"hoi260047r10","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.036533","article-title":"Value of artificial intelligence for enhancing suspicion of cardiac amyloidosis using electrocardiography and echocardiography: a narrative review.","volume":"14","author":"Grogan","year":"2025","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"hoi260047r11","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/ehf2.15061","article-title":"Predictors of mortality by an artificial intelligence enhanced electrocardiogram model for cardiac amyloidosis.","volume":"12","author":"Amadio","year":"2025","journal-title":"ESC Heart Fail"},{"issue":"2","key":"hoi260047r12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jcmg.2023.10.010","article-title":"Current and evolving multimodality cardiac imaging in managing transthyretin amyloid cardiomyopathy.","volume":"17","author":"Alwan","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"hoi260047r13","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jaccao.2026.02.004","article-title":"Disease prognosis and progression in transthyretin amyloidosis: JACC: CardioOncology state-of-the-art review.","volume":"8","author":"Vaishnav","year":"2026","journal-title":"JACC CardioOncol"},{"issue":"21","key":"hoi260047r14","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1002\/sim.8570","article-title":"Graphical calibration curves and the integrated calibration index (ICI) for survival models.","volume":"39","author":"Austin","year":"2020","journal-title":"Stat Med"},{"key":"hoi260047r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.knosys.2022.110234","article-title":"SurvSHAP(t): time-dependent explanations of machine learning survival models.","volume":"262","author":"Krzyzinski","year":"2023","journal-title":"Knowl Based Syst"},{"issue":"1","key":"hoi260047r16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jamacardio.2024.4578","article-title":"Kidney outcomes in transthyretin amyloid cardiomyopathy.","volume":"10","author":"Ioannou","year":"2025","journal-title":"JAMA Cardiol"},{"issue":"9","key":"hoi260047r17","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1093\/ndt\/gfad006","article-title":"Pathological spectrum of hereditary transthyretin renal amyloidosis and clinicopathologic correlation: a French observational study.","volume":"38","author":"Dang","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"hoi260047r18","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1016\/j.mayocp.2021.04.023","article-title":"Artificial intelligence\u2013enhanced electrocardiogram for the early detection of cardiac amyloidosis.","volume":"96","author":"Grogan","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"hoi260047r19","doi-asserted-by":"publisher","first-page":"5680","DOI":"10.3390\/ijms24065680","article-title":"Machine learning approaches in diagnosis, prognosis and treatment selection of cardiac amyloidosis.","volume":"24","author":"Allegra","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"10","key":"hoi260047r20","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.jacc.2024.11.042","article-title":"Efficacy of acoramidis on all-cause mortality and cardiovascular hospitalization in transthyretin amyloid cardiomyopathy.","volume":"85","author":"Judge","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"hoi260047r21","doi-asserted-by":"publisher","first-page":"398","DOI":"10.4997\/jrcpe.2020.409","article-title":"Retrospective studies\u2014utility and caveats.","volume":"50","author":"Talari","year":"2020","journal-title":"J R Coll Physicians Edinb"},{"key":"hoi260047r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2025.112013","article-title":"In humble defense of unexplainable black box prediction models in healthcare.","volume":"189","author":"van Royen","year":"2026","journal-title":"J Clin Epidemiol"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2853448\/jamacardiology_baj_2026_oi_260047_1790870198.28473.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:00:31Z","timestamp":1791990031000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2853448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2026.3496","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}